Ajanta Pharma to host analyst meet on June 17

0 min read Updated on 13 Jun 2026, 05:53 AM

Reviewed by

Anirudha BScanX News Team

AI Summary

Ajanta Pharma has scheduled a meeting with Domestic Institutional Investors (DIIs) on June 17 and 18, 2026, in Mumbai. The company will conduct one-on-one interactions during this conference. The discussions will be strictly based on information that has already been published by the company.

*this image is generated using AI for illustrative purposes only.

The schedule for these meetings is subject to change, and any alterations may occur due to exigencies on either side. The intimation was submitted pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The following table outlines the details of the scheduled meeting:

#	Date of Conference	Conference Name	Type of Meeting	Place
1	17th & 18th June 2026	Domestic Institutional Investors (DII's)	one on one	Mumbai

Gaurang Shah, Sr. VP - Legal & Company Secretary, signed the intimation on June 12, 2026.

Historical Stock Returns for Ajanta Pharma

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-0.39%	+6.22%	+2.18%	+18.09%	+18.29%	+139.51%

What key topics are DIIs likely to focus on during these one-on-one interactions?

How might the outcomes of these meetings influence Ajanta Pharma's stock performance in the short term?

Could this meeting signal upcoming strategic shifts or new product launches by Ajanta Pharma?

Read Next Article

Ajanta Pharma promoter sells 2.76% stake via open market

1 min read Updated on 09 Jun 2026, 03:53 PM

Reviewed by

Suketu GScanX News Team

Add as a preferred
source on Google

AI Summary

Ravi Agrawal Trust sold 34,50,000 equity shares of Ajanta Pharma on June 9, 2026, reducing its stake from 13.00% to 10.24%. The open market transaction, representing 2.76% of the paid-up capital, was disclosed under SEBI regulations.

*this image is generated using AI for illustrative purposes only.

Ravi Agrawal Trust, a promoter group entity of Ajanta Pharma , sold 34,50,000 equity shares on June 9, 2026, reducing its stake in the pharmaceutical company. The transaction, executed via the open market, represented 2.76% of the company's paid-up equity share capital. Following the sale, the trust's holding has decreased to 10.24% of the total voting capital.

The disclosures were submitted to the stock exchanges pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Additionally, the company filed the necessary details under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The filing confirmed that the shares sold carried voting rights and that no other instruments such as warrants or convertible securities were involved in the transaction.

Shareholding Details

The table below outlines the changes in the shareholding pattern of Ravi Agrawal Trust following the disposal of shares:

Parameter	Number of Shares	% of Total Share Capital
Holding Before Sale
Shares carrying voting rights	1,62,42,904	13.00
Shares encumbered	57,56,777	4.61
Transaction Details
Shares sold	34,50,000	2.76
Holding After Sale
Shares carrying voting rights	1,27,92,904	10.24
Shares encumbered	57,56,777	4.61

The equity share capital of Ajanta Pharma remains unchanged at ₹ 24,98,71,248, comprising 12,49,35,624 shares of ₹ 2 each. Ravi Agrawal, acting as the trustee of Ravi Agrawal Trust, confirmed the sale in the disclosure addressed to BSE Limited and the National Stock Exchange of India Limited.

Historical Stock Returns for Ajanta Pharma